BioDue
On 18 May 2015 BioDue S.p.A. obtained the admission of the shares to the AIM Italia market organized and managed by Borsa Italiana. The start of negotiations took place on 20 May 2015.
Integræ SIM acted as the Global Coordinator of the private placement and is currently a Specialist of the Issuer. The total amount of the collection in the IPO was approximately Euro 4 million entirely in a capital increase.
The placement price is equal to € 3.55. On the first negotiating day, the security recorded a closing price of Euro 4.82 with a +35.77% increase compared to the Placement Price.
The enterprise. BioDue develops, manufactures, and markets medical devices, dermo-cosmetic products, and food supplements (solids and liquids) with a particular focus on phytotherapeutic preparations. The company operates both on behalf of large national and international pharmaceutical companies (“Industrial Division”) and for its brands (“Pharcos, Selerbe, and Biofta Divisions” dermatological, phytotherapeutic, and ophthalmic products).
Ultima Ricerca BioDue
BREAKING NEWS| In its press release dated July 30, 2026, Siav SpA Società Benefit, Italy’s leading provider of Enterprise Content Management and Business Process Outsourcing solutions, announced the completion of the acquisition of 100.0% of the share capital of IT Consult S.r.l., an Italian software company specializing in proprietary solutions for document management, digital processes, and cloud services. The transaction was completed following the fulfillment of all contractual conditions precedent. The total consideration amounts to approximately € 3.40 million, structured as 60.0% in cash and 40.0% through a reserved capital increase. The cash consideration will be paid in three equal installments, each representing 20.0% of the purchase price: the first installment was paid at closing, while the remaining two will be settled by December 31, 2026, and March 31, 2027, respectively. The equity component was settled on the date of the announcement through the full subscription of the reserved capital increase allocated pro rata to the selling shareholders. The capital increase, approved by the Board of Directors on July 23, 2026, under the partial exercise of the authority granted by the Extraordinary Shareholders’ Meeting, involved the issuance of 480,984 new ordinary shares, with no nominal value, at a subscription price of € 2.81 per share, for a total value of approximately € 1.35 million. In addition, the agreement includes an earn-out mechanism of up to € 1.00 million, linked to the adjusted EBITDA achieved by IT Consult during the 2026 and 2027 financial years. Following the closing, the new Board of Directors of IT Consult consists of Nicola Voltan as Chairman, Giovanni Marrè as Chief Executive Officer, and Daniele Boggian as Director. From a strategic perspective, the acquisition is fully aligned with Siav’s external growth strategy and forms part of a broader organizational and managerial transformation. The integration of technological capabilities complementary to those already within the Group and the expansion of its product offering are expected to support future growth opportunities. Furthermore, the acquisition is intended to strengthen Siav’s positioning in strategically important markets, create new commercial opportunities, and enhance the quality and predictability of revenues, while ensuring business continuity and preserving the valuable know-how developed by IT Consult over the years. In light of the information disclosed in the press release, we confirm our recommendation: target price € 5.70, rating BUY, risk Medium. |
